HC Wainwright & Co. Downgrades Surface Oncology to Neutral, Announces $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Surface Oncology (NASDAQ:SURF) from Buy to Neutral and set a $5 price target.
June 20, 2023 | 10:09 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Surface Oncology downgraded to Neutral from Buy by HC Wainwright & Co. with a $5 price target.
The downgrade from Buy to Neutral by HC Wainwright & Co. analyst Swayampakula Ramakanth is likely to have a negative short-term impact on Surface Oncology's stock price. The announcement of a $5 price target may also influence investor sentiment and potentially lead to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100